<div><p>We developed and optimized a high-throughput project workflow to generate renewable recombinant antibodies to human proteins involved in epigenetic signalling. Three different strategies to produce phage display compatible protein antigens in bacterial systems were compared, and we found that <i>in vivo</i> biotinylation through the use of an Avi tag was the most productive method. Phage display selections were performed on 265 <i>in vivo</i> biotinylated antigen domains. High-affinity Fabs (<20nM) were obtained for 196. We constructed and optimized a new expression vector to produce <i>in vivo</i> biotinylated Fabs in <i>E</i>. <i>coli</i>. This increased average yields up to 10-fold, with an average yield of 4 mg/L. For 118 antige...
7noDuring the last 20 years in vitro technologies opened powerful routes to combine the generation o...
Abstract Background Genomic, transcriptomic and proteomic projects often suffer from a lack of funct...
During the last 15 years in vitro technologies opened powerful routes to combine the generation of l...
We developed and optimized a high-throughput project workflow to generate renewable recombinant anti...
After the completion and refinement of the human genome, the characterization of individual gene pro...
Phage display technology has emerged as the dominant approach in antibody engineering. Here I descri...
abstract: Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeu...
Despite the wealth of commercially available antibodies to human proteins, research is often hindere...
Antibodies leverage on their unique architecture to bind with an array of antigens. The strength of ...
Recombinant human antibody technology has been the cornerstone of the uprising of biologics in the p...
Phage display technology has been widely used for antibody affinity maturation for de-cades. The lim...
Our increasing understanding of disease mechanisms coupled with technological advances has facilitat...
The antibody repertoires of transgenic mice expressing human heavy chain only antibodies (HCAbs) can...
Abstract Background The demand of monospecific high affinity binding reagents, particularly monoclon...
<div><p>Phage display technology has been widely used for antibody affinity maturation for decades. ...
7noDuring the last 20 years in vitro technologies opened powerful routes to combine the generation o...
Abstract Background Genomic, transcriptomic and proteomic projects often suffer from a lack of funct...
During the last 15 years in vitro technologies opened powerful routes to combine the generation of l...
We developed and optimized a high-throughput project workflow to generate renewable recombinant anti...
After the completion and refinement of the human genome, the characterization of individual gene pro...
Phage display technology has emerged as the dominant approach in antibody engineering. Here I descri...
abstract: Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeu...
Despite the wealth of commercially available antibodies to human proteins, research is often hindere...
Antibodies leverage on their unique architecture to bind with an array of antigens. The strength of ...
Recombinant human antibody technology has been the cornerstone of the uprising of biologics in the p...
Phage display technology has been widely used for antibody affinity maturation for de-cades. The lim...
Our increasing understanding of disease mechanisms coupled with technological advances has facilitat...
The antibody repertoires of transgenic mice expressing human heavy chain only antibodies (HCAbs) can...
Abstract Background The demand of monospecific high affinity binding reagents, particularly monoclon...
<div><p>Phage display technology has been widely used for antibody affinity maturation for decades. ...
7noDuring the last 20 years in vitro technologies opened powerful routes to combine the generation o...
Abstract Background Genomic, transcriptomic and proteomic projects often suffer from a lack of funct...
During the last 15 years in vitro technologies opened powerful routes to combine the generation of l...